Organic Active Ingredients TRIZ Cases

Microneedles create nanochannels through the skin barrier, allowing wet formulations with nanocarriers to deliver both small and large molecules effectively.

Substituted amino acid compounds inhibit alpha v beta 6 integrin to address unproven long-term survival options in fibrotic disease treatment.

Spirocyclic indane derivatives target specific structural classes to resolve insufficient IL-17 modulation in inflammatory disorders.

Triazole derivatives improve receptor binding and bioavailability to treat obesity and inflammation.

Dissolving lercanidipine hydrochloride in alcohol and adding an aliphatic ester solvent yields pure polymorph form V crystals.

Optimized pyrrolopyridine structures inhibit HIV-1 integrase while reducing drug toxicity and resistance.

Formula I bicyclic compounds inhibit HBV and HDV replication, addressing the lack of a cure for severe hepatitis infections.

Phosphorus prodrugs of troxacitabine bypass rate-limiting phosphorylation to achieve high liver concentrations while reducing organ toxicity.

Novel pantothenic acid derivative with specific acyl groups enhances skin permeability and biological absorption.

Vamorolone binds the glucocorticoid receptor to treat congenital adrenal hypoplasia without causing growth stunting or bone fragility.

Combining thienopyrimidine inhibitors with chemotherapeutic agents overcomes cancer resistance via synergistic tumor growth inhibition.

Inhibitory nucleic acid targeting miR-128 modulates mitochondrial metabolism proteins to restore muscle function in dystrophic tissue.

A nicotine solution combines unprotonated and protonated forms to deliver a balanced inhalation experience.

Heterotrophic microalgae cultivation yields purified polysaccharides for topical skin care formulations.

A PASTE system uses a nickase and reverse transcriptase to integrate nucleic acids into the genome.

Removing live cells from amnion tissue eliminates stringent storage requirements while maintaining therapeutic efficacy through retained growth factors.

A pregabalin solid composition uses a polyvinyl acetate and cross-linked polyvinylpyrrolidone matrix to sustain drug release.

IGF-1R antisense oligodeoxynucleotides eliminate M2 macrophages, overcoming tumor-induced immunosuppression and enhancing anti-tumor responses.

2-deoxy-monosaccharide esters inhibit glycolysis in tumor cells while sparing normal cellular energy production.

Solid oral bolus delivers buparvaquone via controlled release, replacing unstable injectable treatments that require veterinary intervention.

Liposomal CoQ10 delivery overcomes chemotherapeutic resistance by downregulating Bcl-2 and reactivating p53 to induce apoptosis.

VEGF-A specific siRNAs cleave target mRNA transcripts to inhibit pathological angiogenesis in ocular tissues.

Formula I compounds address failed human drug development by optimizing chemical parameters to balance efficacy with manageable synthesis complexity.

Benzoyloxy-substituted compound achieves selective ACAT2 inhibition to treat arteriosclerosis without side effects from non-specific inhibitors.

GS-7977 and ribavirin combination eliminates interferon to reduce side effects while maintaining effective hepatitis C virus suppression.

Anti-CD45RC antibody targets CD45RC+ cells to prevent transplant rejection while preserving systemic immune competence against non-donor antigens.

Incorporating microRNA hairpins into oncolytic viruses boosts therapeutic effectiveness through enhanced cytotoxicity and replication.

Targeted 23-substituted bile acid compounds modulate the TGR5 receptor to address inadequate treatment effectiveness for metabolic and inflammatory diseases.

Combining citrulline with arginine overcomes the slow absorption of direct arginine, providing immediate relief from exercise-induced muscle fatigue.

Collaborative Enzyme Enhanced Reactive Immunoassay detects cMET and HER1 activation states to guide gastric cancer treatment selection.

Sialyllactose addresses the trade-off between inflammation relief and joint health by stimulating chondrocyte activity without cytotoxicity.

Pyrrolopyrazine compounds antagonize alpha v integrin-mediated activation of latent TGF-beta, addressing unmet needs in fibrosis and cancer treatment.

Synthetic hydrogel immunoisolation protects cells from immune rejection while enabling physiologic estrogen feedback regulation.

Oral S1P receptor modulator dosage regimen manages cardiac side effects via preliminary screening and feedback loops to improve compliance.

Benzo[d]furan-based SIRT1 activators resolve insufficient efficacy of resveratrol by enhancing potency to treat obesity, insulin resistance, and fatty liver.

Isoxazole and pyrazole carboxamides target tau pathology to halt neurodegenerative disease progression.

Administering anti-mycoplasma agents before chemotherapy overcomes mycoplasma-induced multi-drug resistance in tumor cells.

Isolating a novel 7H-azulene isoquinolinone alkaloid from Acorus calamus L. via sequential solvent extraction and column chromatography.

Formula I compounds inhibit tyrosine and serine/threonine kinases by targeting EGFR mutants, addressing the lack of effective cancer treatments.

AAV vectors deliver condensed tuberin proteins to modulate mTOR signaling pathways in target cells.

In-situ riboflavin crosslinking restores intervertebral disc elasticity and stability, preventing herniation recurrence without surgical removal.

Pyrrolopyridine compounds serve as PET radiotracers to image tau aggregates, replacing invasive histology with non-invasive diagnosis.

Compounds inhibit Z-antitrypsin polymerization by binding cryptic sites, preventing liver damage from accumulated mutant proteins.

Anti-PD-1 nucleic acid aptamers bind to the PD-1 receptor to neutralize its inhibitory activity and enhance T cell proliferation.

IGSF1 biomarker predicts MET inhibitor response in HGF-independent cancers to improve treatment efficacy.

High dimer vitamin E derivatives solubilize non-polar compounds in aqueous beverages, preventing organoleptic deterioration.

Blocks TLR4 signaling with naltrexone and acetaminophen to treat emotional pain without opioid overdose risk.

Soluble fiber and linolenic acid ratios increase lean mass in obese pets while reducing blood triglycerides.

UNA oligomers selectively bind V30M TTR mRNA via complementary base pairing, achieving allele-specific knockdown without suppressing wild-type production.

Fusion proteins combining ACVR domains inhibit ectopic bone formation by blocking mutated receptors, simplifying treatment complexity.

Fluorinated radiolabeled compounds improve diagnostic accuracy by targeting alpha-synuclein aggregates while crossing the blood-brain barrier.

Selective PREP inhibition lowers PGP concentrations, reducing lung inflammation and neutrophil recruitment without broad immunosuppression side effects.

Extracting specific long-chain MUFAs from fish oil suppresses fatty acid synthesis to lower blood glucose and cholesterol levels.

Segmenting active ingredients into distinct layers prevents degradation while optimizing bioavailability.

Formula I-V agents inhibit malignant cell growth, addressing low efficacy in current cancer therapies.

Short-acting clevidipine infusion controls blood pressure in acute heart failure while minimizing overshoot hypotension risks.

Pyrimidine-phthalazinyl structures target overexpressed Aurora kinases to resolve the trade-off between broad efficacy and selective toxicity.

Red blood cell coupled nanoparticles shuttle drugs to target organs while minimizing liver uptake.

Local implantation of a (Z)-butylidenephthalide formulation overcomes low systemic efficacy by targeting invasive residual cells.

Cholesterol conjugation enables iRNA agents to cross the blood-brain barrier, resolving delivery bottlenecks for huntingtin gene silencing.

Heterocyclic derivatives inhibit beta-secretase to reduce amyloid beta protein production.

miR-10a-5p and miR-10b-5p mimics target specific metabolic pathways to lower blood glucose levels and reduce body weight in type 2 diabetes treatment.

Formula I and II compounds suppress premature stop codons to restore SBDS protein expression, addressing inconsistent results from existing read-through drugs.

IAP inhibitors modulate apoptotic pathways in antigen-presenting cells to overcome insufficient immune response induction against tumor-associated antigens.

A topical pharmaceutical composition using diclofenac epolamine salts and volatile silicones to deliver active ingredients through the skin.

A 64Zn-enriched zinc composition enhances insulin function and metabolic status through improved isotopic absorption.

Nanocrystalline hydroxyapatite and collagen formulation extrudes through an 18 gauge cannula with minimal force.

A minoxidil composition with penetration enhancers delivers active agents through the scalp barrier.

Segmented storage in a vial-closure cap keeps solid melatonin stable while liquid magnesium pidolate prevents swallowing issues until mixing.

Amino acid compositions disrupt protective biofilm matrices, restoring antimicrobial susceptibility against resistant bacterial and fungal infections.

Prodrug compounds target cancer cells overexpressing fatty acid uptake proteins to deliver cytotoxic payloads, reducing off-target damage to healthy tissues.

Non-ionic surfactants mediate rapamycin dispersion in hydrophobic polyester carriers, preventing aggregation to enable sterile filterability.

KL1333 promotes ATP production via NAD(P)H:dehydrogenase activity, addressing the lack of approved medicines for primary mitochondrial diseases.

Carbonyldiimidazole activates carboxylic acids to form acyl imidazole intermediates for scalable cyclization without complex batch workups.

A kinetic screening method identifies modified inhibitor scaffolds that delay protein aggregation by targeting specific nucleation steps.

Combining magnetic T cell depletion with cyclophosphamide debulking resolves graft rejection versus GVHD trade-offs for durable engraftment.

Somatostatin receptor binding moieties attach to nanoparticles, reducing systemic toxicity by selectively targeting cancer cells.

Site-specific formylglycine linkages resolve heterogeneous drug attachment in anti-CD25 antibody-maytansine conjugates.

Enzymatic de-esterification of cranberry extract fractions enhances intestinal bioavailability and antibacterial activity.

Removing the inner limiting membrane exposes the retina, allowing fluid replacement material to hold agents in place and bypass transient detachment trauma.

Heteroaryl-fused quinazoline compounds inhibit cyclin-dependent kinases while reducing toxicity through improved selectivity.

An Arid5A inhibitor therapeutic agent suppresses IL-6 mRNA stabilization, reducing mortality from excessive inflammatory responses in sepsis.

Aptamer binding to Factor D inhibits the alternative pathway, addressing untreated dry AMD and geographic atrophy.

Substituted triazole compounds decrease uric acid levels and increase excretion to treat gout and hyperuricaemia.

Colchicine inhibits microtubule polymerization to recover heart function and reduce arrhythmia burden in LMNA-related dilated cardiomyopathy patients.

A sphinganine and creatine composition stimulates follicular cells to promote hair growth.

Converting the active ingredient to a sodium salt eliminates melt formation during granulation, ensuring consistent drug content in osmotic release devices.